Oncogene - To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control Skip to main content Thank you for visiting nature.com.

Yeast cytosine deaminase (yCD) is a well-characterized prodrug/enzyme system that converts 5-fluorocytosine (5-FC) to 5-fluorouracil (5-FU), and has been combined with oncolytic viruses. However ...

Researchers have developed the downstream section of a new streamlined production method for an emerging virus class.

Replication-selective oncolytic viruses are a rapidly expanding therapeutic platform for cancer. Professor Wang Shengdian and his group from the Key Laboratory of Infection and Immunity, ...

Oncolytic virus therapy is not a new discovery, but it may now be positioned as the next major breakthrough in cancer treatment following the success of checkpoint inhibitors in immunotherapy. An ...

Oncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, offering a unique potential to selectively target malignant cells while sparing normal tissues.

Replication-selective oncolytic viruses are a rapidly expanding therapeutic platform for cancer. Professor Wang Shengdian and his group from the Key Laboratory of Infection and Immunity, Institute of ...

Unlike other clinical oHSVs, CAN-3100 includes the ICP34.5 gene, which is often excluded from clinical oHSV candidates because it causes human disease in unmodified forms of the virus.

Oncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, offering a unique potential to selectively target malignant cells while sparing normal tissues.

But Replimune’s therapy, an oncolytic virus, has better data in melanoma, and the company plans a 2024 FDA submission in this skin cancer. By Frank Vinluan on December 05, 2023 6:45 pm Share ...

Oncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, offering a unique potential to selectively target malignant cells while sparing normal tissues.

Immune landscape and response to oncolytic virus-based immunotherapy. Higher Education Press . Journal Frontiers of Medicine DOI 10.1007/s11684-023-1048-0 ...